Trade Mark Journal No.2026/019 8 May 2026
UK00004375783 20 April 2026 (5)
International priority date claimed: 26 November 2025
(United States of America)
(99518171)
- Class 5
- Pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders.
Vertex Pharmaceuticals Incorporated
Representative: Haseltine Lake Kempner LLP